Achilles therapeutics presents encouraging phase i/iia update on clonal neoantigen reactive t cells in advanced nsclc and melanoma at esmo io congress 2022

- early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced nsclc -

ACHL Ratings Summary

ACHL Quant Ranking